On August 24, 2026, a new publication concerning bivalirudin was released. Titled "Safety of Bivalirudin Use in Critically Ill Children: A Single-Center Experience," the paper appears in Pediatric Critical Care Medicine, a journal affiliated with the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
The publication is identified as a single-center experience report focused on bivalirudin use within a critically ill pediatric population. Bivalirudin remains an approved compound, and this article represents new literature added to the existing body of research on its use in clinical settings.
No specific findings, outcomes, or safety conclusions from the study have been provided beyond the title and publication details listed here. As with any single-center report, the scope and context of the data described in the paper should be considered when reviewing the publication directly.
Readers interested in the full findings, methodology, and conclusions of this study are encouraged to consult the original article through the source listed below. This brief serves only to note the publication's release and its indexing details, without interpreting or summarizing its content.
For additional background on bivalirudin, readers can consult the compound overview.